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Extranodal natural killer (NK)/T-cell lymphoma of nasal type (NKTCL) is a malignant disorder of cytotoxic lymphocytes of NK
or more rarely T cells associated with clonal Epstein-Barr virus infection. Extranodal NKTCL is rare in Western countries, but in
Asia and Central and South America it can account for up to 10% of non-Hodgkin’s lymphomas. It is an aggressive neoplasm
with very poor prognosis. Although the pathogenesis of extranodal NKTCL remains poorly understood, some insights have been
gained in the recent years, especially from genome-wide studies. Based on our own experience and knowledge of the literature, we
here review some of the genomic and functional pathway alterations observed in NKTCL that could provide a rationale for the
development of innovative therapeutic strategies.
1.Introduction
The term extranodal natural killer/T-cell lymphoma
(NKTCL) refers to a group of clonal proliferations of
cytotoxic lymphocytes of natural killer (NK) or, more rarely,
T-cell types, with peculiar clinicopathologic features, arising
mainly as tumors or destructive lesions in the nasal cavity,
maxillary sinuses, or palate [1]. More rarely, extranodal
NKTCL may present in other extranodal sites such as skin,
testis, lung, or gastrointestinal tract and tend to have a more
adverse clinical outcome [2–4]. This is particularly true
when one deﬁnes nonnasal cases as extra upperaerodigestive
tract cases as in the study of Lee et al. which reports
survival rates of 20% versus 54% for the patients with
nasal and upper airway region localizations [4]. However,
as noted by several authors, many nonnasal NKTCL might
represent disseminated nasal NKTCL, knowing that such
dissemination can occur early in the clinical course of
the disease and toward sites that are localizations where
nasal NKTCL will metastasize to. Besides the more adverse
clinical features, for which the underlying mechanisms
need to be deﬁned, there are no signiﬁcant diﬀerences
in age, gender, ethnicity, bone marrow involvement,
hemophagocytosis, or immunophenotypic proﬁles between
nasal and nonnasal NKTCL. Very rare cases with primary
lymph node involvement have also been described [5].
Extranodal NKTCL shows a wide cytological spectrum and
is characterized by frequent features of angioinvasion and
angiocentrism, which often result in coagulative necrosis.
Typically, tumor cells express cytoplasmic CD3ε,C D 2 ,
CD56, lack CD5, CD4, and CD8, and have an activated
cytotoxic immunophenotype with expression of perforin,2 Journal of Biomedicine and Biotechnology
granzyme B, and TiA1. The cell of origin of these tumors has
been debated. Indeed, the identiﬁcation of CD3 expression
in tumor cells in necrotic lesions has led to the terminology
of angiocentric T-cell lymphoma [6–8] adapted in the REAL
classiﬁcation [9],before itwasdemonstrated that tumorcells
express several chains of the CD3 complex in the cytoplasm,
but lack T-cell receptors (TCR) and have TCR genes in a
germline conﬁguration, consistent with an NK-cell origin
[10, 11]. If the majority of NKTCL are likely to originate
from mature NK cells, a small proportion of cases, with
expression of γδ or αβ TCR appear to derive from cytotoxic
T lymphocytes, reﬂected in the “NK/T” cell terminology.
Extranodal NKTCL represents the major group of
mature NK cell neoplasms in the recently revised WHO clas-
siﬁcation ofhematolymphoidtumors, which also includethe
aggressive NKcell leukemia(ANKL)and a provisional group
ofchronic NK-celllymphoproliferativedisorderofuncertain
malignant potential, most likely related to T-cell large
granular lymphomas [1]. Importantly, both NKTCL and
ANKL are Epstein-Barr virus- (EBV-) associated neoplasms
as the virus is found in their tumor cells [12, 13]. Although
the precise role of the virus in the etiology of the disease is
poorlyunderstood,thestudyofEBVgenepolymorphismhas
shown that tumor cells are clonally infected as opposed to
normal nasal tissues [14,15].CirculatingEBVviral load isan
importantprognosticfactor,andplasmaEBVDNAlevelscan
also be used for disease monitoring [16]. In this respect, the
incidence of NKTCL parallels the geographic distribution of
EBV infection with prevalence in the Asian and Central and
South American populations, where it can account for up to
10% of non-Hodgkin’s lymphomas [17–19].
Despite a localized presentation in most patients, extra-
nodal NKTCL is an aggressive disease with poor prognosis.
T h e5 - y e a rs u r v i v a lr a t ei sl e s st h a n5 0 % .I nt h ea b s e n c e
of eﬀective treatment, the median survival for advanced-
stage disease is only 6–12 months [19–22]. The retrospective
International Peripheral T-cell Lymphoma project recently
reportedamedianoverallsurvivalof7.8monthsforNKTCL,
corresponding to the poorest survival among all T-cell
lymphoma entities [2]. Therefore, despite progress with
combined ﬁeld radiotherapy and chemotherapy, autologous
bone marrow transplantation and the promising eﬀect of L-
asparaginase treatment in relapsed cases [16, 23], NKTCL
remains diﬃcult to cure, and the need for alternative
therapeutic strategies has prompted researchers to explore
oncogenic pathways involved, to provide new molecular tar-
gets. This review will focus on the these potential molecular
pathways that have been implicated in the physiopathology
of NKTCL, in particular through the lights shed by several
recently reported genome-wide proﬁling studies [24–30].
2.EBVInfectionandViral ProteinExpression
Several lines of evidence point at EBV as a major player in
the pathogenesis of NKTCL. First of all, when dealing with
an EBV-associated malignancy, one can think of NKTCLas a
potentially highly immunogenic lymphoma that couldbene-
ﬁtfromcellularimmunotherapiestargetingtheviralantigens
as in posttransplant B-cell lymphoproliferative disorders
[31]. These B-cell proliferations, like the in vitro infected B-
cell-derived lymphoblastoid cell line (LCL), express the full
spectrum of EBV latent proteins (latency III). The latent
phase consists of the maintenance of the EBV genome as
a circular episome that is replicated by the cellular DNA
polymerase. Latent type III infection is associated with the
expression of six EBV-encoded nuclear antigens (EBNA):
EBNA1, EBNA2, EBNA2A, EBNA3B, EBNA3C, and EBNA
leader protein (EBNA-LP); three cell surface proteins: latent
membrane protein (LMP) 1, LMP2A, and LMP2B; two EBV-
encoded RNAs: EBER1 and EBER2. Among these proteins,
the EBNA3s are believed to be particularly immunogenic for
the generation of speciﬁc cytotoxic T lymphocytes (CTL).
However, similarly to Hodgkin’s lymphoma, NKTCL is
believed to be in latency II, with a more restricted pattern
of viral proteins expressed, limited to EBNA1, LMP1, and
LMP2 [32]. EBNA1 is required for the maintenance of
viral episomes and expressed in all latency phases. LMP1
is the main transforming protein of EBV. It is essential
for EBV-induced B-cell transformation in vitro, acting like
a constitutively activated tumor necrosis factor receptor
family member, activating NF-κB pathway and promoting
cellsurvival.LMP2AandLMP2Baregeneratedbyalternative
splicing and, although not essential for B-cell transforma-
tion, can also promote proliferation and survival. However,
LMP2 has only been demonstrated at the transcriptional
level in NKTCL. LMP1 expression is also variable, and when
expresseditisoftenlimitedtoasubpopulationoftumorcells,
possibly under the pressure of host immune surveillance.
Despite these challenging conditions, attempts have been
made to generate in vitro LMP2-speciﬁc CTL using antigen-
presenting cells overexpressing LMP2, to treat Hodgkin’s
lymphoma and NKTCL patients [33]. The cytotoxic activity
of these LMP2-speciﬁc CTL have been conﬁrmed against
NKTCL-derived cell line, which led to the discovery of a
unique alternative transcript of LMP2 (LMP2-TR) that uses
a new promoter located in the terminal repeat region of
the episomal EBV, not expressed in B-LCL [34]. LMP2-
TR may constitute a promising target for adoptive cellular
immunotherapy in NKTCL.
EBV is a B-lymphotropic virus, infecting B cells through
interaction with its cellular receptor CD21, and establishing
a lifelong infection in more than 90% of the human adult
population. Although the precise mechanism involved in
NK- or T-cell infection is unknown, passive acquisition of
CD21 in the NK/T-cells by membrane fragment exchange
during cytotoxic interaction, a process known as trogo-
cytosis, has been proposed [35, 36]. Chronic active EBV
infection (CAEBV) was ﬁrst recognized as severe illness
related to chronic or persistent EBV infection [37, 38].
CAEBV is a life-threatening disease characterized by infec-
tious mononucleosis-like symptoms with virus-associated
hemophagocytic syndrome. Like in NKTCL, clonal prolifer-
ations of EBV-infected NK- or T-cells are seen in patients
with CAEBV, making this disease more likely a chronic
lymphoproliferativedisorderorapremalignantstageassome
CAEBV patients can actually develop subsequent NKTCL
[39]. Whether the EBV-host interaction may play a roleJournal of Biomedicine and Biotechnology 3
in the development of NKTCL is still a pending question.
Performing comparison of EBV and cellular gene expression
proﬁling in NKTCL- and CAEBV-derived cell lines, Zhang
et al. reported the transcription of lytic phase genes such
as BZLF1, BARF1, BFLF2, and BDLF3, despite the absence
of virion DNA production and cellular gene signature
implicating mainly cell cycle and apoptosis-related genes
such as TNFRSF10D, CDK2, Hsp90, IL12A, and PDCD4
[30]. Beside the expression of latency II genes, expression
in NK/T-cell lines, of lytic phase genes (such as BZLF1)
capable to interact with multiple cell cycle control proteins
is intriguing. EBV may exert oncogenic eﬀects through the
production of cytokines such as Interleukin 9 (IL-9) [26]
and IL-10 [40]. EBV-induced production of IP10/MIP2
chemokines may contribute to vascular damage and necrosis
[41]. Obviously, the way viral gene products interact with
cellular host metabolism needs to be clariﬁed and may lead
to novel targets for therapies.
3.NKCellAntigensandCytotoxicActivity
Irrespective of their NK, αβ-, or γδ-T-cell lineage, NKTCL is
a lymphoma ofactivated cytotoxiclymphocytesas evidenced
by the expression of cytotoxic molecules such as perforin,
granzyme B, and TIA1 [42]. Whereas T cells use their TCR
for antigen recognition and controlof their speciﬁc cytotoxic
activity, NK cells use MHC class I-speciﬁc NK cell receptors
(NKR) for this purpose [43]. NK cells are part of the innate
immune system involved in the immunosurveillance [44].
Engagement of inhibitory NKR by self-MHC class I on
potential target cells inhibits cytotoxicity whereas loss of
MHC class I expression due to transformation or viral infec-
tion, results in a loss of this inhibition. There are two types
of NKR: the killer immunoglobulin-like receptors (KIR) and
the killer cell lectin-like receptors (KLR or CD94/NKG2
complexes). KLR as well as other NK cell markers like CD56
can also be expressed by αβ-o rγδ-cytotoxic T cells. The
KIR locus located on human chromosome 19, exhibits a
substantial haplotypic and allelic diversity [45, 46]. The KIR
haplotypes have been separated into two groups, containing
f r o m7t o1 2g e n e s[ 47]. The expression of KIR at the
cell surface is clonally distributed, meaning that a clonal
NK/T-cell population is expected to express a restricted KIR
repertoire as shown in NKTCL [48–50]. Another example
of the interest of KIR in malignant lymphomas is given by
KIR3DL2 that proved to be a valuable tool in the diagnosis,
and perhaps a clinical target, of S´ ezary syndrome, a cuta-
neous CD4+ T-cell lymphoma with systemic dissemination
[51–53]. KLR are C-type lectin receptors that precede the
expression of KIR during NK cell development. They consist
of molecules of the NKG2 family such as NKG2A (KLRC1),
NKG2C (KLRC2), or NKG2E (KLRC3), form heterodimer
with earlier expressed CD94 at the surface of maturing
NK cells [54]. In addition to immature NK cells, a subset
of mature NK cells also lack CD94/NKG2 expression as
a consequence of the clonal diversiﬁcation phenomenon.
Interestingly, expression of CD94 has been associated with
a betterprognosis in NKTCL [55]. AlthoughNK activity was
identiﬁed from the initial description of ANKL [56, 57], the
cytotoxic activity of the NKTCL tumor cells has not been
particularly investigated due to the diﬃculty to isolate these
cells.
4.Survival/Apoptosis
The mechanisms by which NKTCL cells survive and escape
immune surveillance are unknown. One way for an NKTCL
tumor cell to escape anti-EBV immunity is to lower its
expression of EBV antigens, particularly LMPs proteins. It
is also known that cytotoxic eﬀector cells have a proper
way to resist to their own cytotoxic agents [58]. The main
cytotoxic pathway used by NK and CTL involves the release
from specialized granules of cytotoxic molecules including
perforin and granzymes, triggering aprocess leading to DNA
fragmentation and apoptosis. In particular, granzyme B
(GZMB), by activating directly or indirectly caspase-3, leads
to rapid execution of apoptosis. SERPINB9 (also known as
PI9) is a GZMB-speciﬁc serine protease inhibitor that can
protect eﬀector cells from their own cytotoxic activity. It has
been shown that SERPINB9 can make hepatocytes resistant
to lysis by CTL or NK cells [59] and may participate to the
mechanism for tumor escape in NKTCL [60]. Interestingly,
its loss of expression was described as a poor prognostic
factor in a study of 48 NKTCL patients [20].
Although it seems that tumor cells are resistant to
the killing via GZMB, NKTCL are frequently associated
with zonal tumor cell death, tissue necrosis, and vascular
damage. The production of chemokines like CXCL9 (Mig)
and CXCL10 (IP10), in response to interferon γ released
by activated tumor cells, may contribute to the observed
damages [41, 61]. Although Fas (CD95) as well as Fas ligand
(FASL/CD95L)are frequentlywell expressed inNKTCLcells,
mutations of the FAS gene are observed in 50 to 60% of
cases, most likely contributing to resistance to apoptosis
[62]. Indeed, most of the FAS gene mutations are frameshift
mutations arising in the death domain, leading to mutated
proteinsonthecellsurface,unabletotransducetheapoptotic
signal [63]. High expression of FASL is also a way for
tumor cells to evade immune response by deleting Fas-
expressing inﬁltrating Tcells.Inline withtheseobservations,
NKTCL has long been known as resistant to combination
chemotherapy. This resistance is also complicated by the
high expression of p-glycoprotein, encoded by multidrug
resistance gene 1 (MDR1)t h a ta c t sa sa ne n e r g y - d e p e n d e n t
eﬄux pump for various drugs [64].
Very recently, survivin (BIRC5), an inhibitor of apop-
tosis frequently involved in tumor oncogenesis, was found
overexpressed in NKTCL [28]. The authors proposed that
survivin could be a useful therapeutic target in NKTCL.
In in vitro studies, they showed that Terameprocol, a
survivin inhibitor, could downregulate survivin expression
and induced apoptosis in NK cell lines.
5.CytogeneticAnalysis
Lymphomas arise from clonal expansion of transformed
lymphoid cells through the accumulation of genetic lesions.4 Journal of Biomedicine and Biotechnology
Currently, no genetic abnormalities speciﬁc for NKTCL have
been identiﬁed. Cytogenetic analyses of NKTCL are diﬃcult
because of necrosis, small-size samples, and contamination
by inﬂammatory reactive cells. Despite these diﬃculties,
several studies using comparative genomic hybridization
(CGH) and loss of heterozygosity (LOH) techniques have
been reported [65–70]. Altogether, these studies identiﬁed
gains at chromosomes 1p, 6p, 11q, 12q, 17q, 20q, Xp,
and losses at 6q, 11q 13q, and 17p. In particular, the
most frequent deletion was observed at 6q21–25 in all but
o n es t u d y .S u ne ta l .t r i e dt od e ﬁ n eam i n i m a lt u m o r
suppressor gene-containing region involved in del6q25 and
identiﬁed a 2.6Mb interval located between TIAM2 and
SNX9 genes [69]. More recently, progress in the DNA chip
technology allowed the development of genome-wide array-
based CGH (aCGH) giving access to better resolutions.
The ﬁrst report, from Nakashima et al., performed with
homemade arrays with 1.35Mb resolution, studied 10 of
ANKLand 17 NKTCLcases and reported diﬀerences in their
genomic alteration patterns (see Table 1)[ 27]. Loss of 7p
(40%) and 17p13.1 (40%) and gain of 1q (43%) occurred
more frequently in ANKL whereas loss of 6q did not. On the
otherhand,lossof6q21–q22.1(35%),6q22.33–q23.2(47%),
6q25.3 (29%), and 6q26-q27 (35%) were more frequent in
NKTCL. Other alterations in NKTCL compared to ANKL
include gain in 2q and loss of 1p36.23–p36.33, 2p16.1–
p16.3, 4q12, 4q31.3–q32.1, 5p14.1–p14.3, 5q34–q35.3, and
11q22.3–q23.3. Two recent studies extended these ﬁndings
by comparing submegabase resolution aCGH and gene
expressionproﬁlingonNKcelllinesaswell asNKTCLtumor
samples [24, 71]. These two studies emphasize recurrent
genomicabnormalitiesobservedinabouthalfofthepatients:
gain of 1q21–q44, and losses of 17p11.2–p13.3 and 6q21.
In particular, this region of del6q21 contains four candidate
tumor suppressor genes, PRDM1, ATG5, AIM1, and HACE1,
which decreased expression was conﬁrmed at the RNA level.
In their study, Iqbal et al. found mutations and methylation
in PRDM1, ATG5,a n dAIM1 in NKTCL cell lines [71].
ATG5 is part of the autophagy pathway implicated both in
apoptosis and in the maintenance of energy homeostasis
during starvation [72]. The role of autophagy in onco-
genesis is, however, the object of controversy [73]. AIM1
which stands for “absent in melanoma-1” is still poorly
characterized but was reported as a good tumor suppressor
gene candidate in malignant melanoma, exerting its eﬀects
through interactions with the cytoskeleton[74]. PRDM1 is a
transcriptional regulator, initially described as a suppressor
of beta-interferon gene expression, that is associated with
the terminal diﬀerentiation of B lymphocytes and T-cell
homeostasis and function [75, 76]. It was found mutated in
some diﬀuse large B-cell lymphomas, and it was concluded
that its inactivation contributes to lymphomagenesis by
blocking diﬀerentiation of postgerminal center B cells to
plasma cells [77]. Loss-of-function due to mutations as well
as transcriptional inhibition by DNA methylation observed
in NK cell lines, suggest a tumor suppressor role of PRDM1
in NKTCL [71].
HACE1 is another candidate tumor suppressor gene [24,
90]. Characterization of the chromosome 6q21 breakpoint,
frequently involved in sporadic Wilm’s tumors, led to the
identiﬁcation of the HACE1 gene [91]. It encodes a member
of the HECT family of E3 ubiquitin ligases that tag speciﬁc
target proteins to degradation by the proteasome or to
control their subcellular localization [85]. Because of their
involvement in controlling crucial signaling pathways, E3
ubiquitin ligases appear as important regulators of cancer
development and therapy. It is downregulated in multiple
human cancers and maps to a prominent tumor-suppressor
region of LOH in many tumors including lymphomas.
HACE1−/− mice are also prone to spontaneous development
of various types of cancers[90]. Our integrated genomicand
transcriptomic analysis of NKTCL tumor samples and cell
lines has shown downexpression of HACE1 gene irrespective
o ft h ep r e s e n c eo fd e l 6 q 2 1a l t e r a t i o n[ 24]. In addition,
we could show by methylation-speciﬁc PCR and product
sequencing(datanot shown) thathypermethylation ofCpG-
177 island located directly upstream of HACE1 locus, is
responsible of the silencing of the diploid gene or the
remaining allele. Although the mechanism of antitumor
action of HACE1 is still unclear, it has been shown that
overexpression of HACE1 in the 293T cell line inhibits cell
proliferation via the degradation of phosphorylated cyclin
D1 [90]. This suggests a possible mechanism for HACE1 to
regulate cell cycle exit by reducing cyclin D1 levels. Existence
of other HACE1 targets is possible as suggested by the recent
identiﬁcation of retinoic acid receptor beta 3 as an HACE1
interacting protein [92].
6.Cell Signaling Pathways
Although the anomaly of signaling pathways involved in the
pathogenesis of NKTCL is not deciphered, progress has been
made in the recent years that will help to deﬁne candidate
therapeutic targets.
6.1. Jak-Stat Pathways. Signal transducers and activators of
transcription, STATs, are transcription factors activated in
response to cytokines or growth factors [80]. The activation
of STAT signaling pathways requires tyrosine phosphoryla-
tion of the STAT proteins that results from their association
with growth factor receptors having intrinsic tyrosine kinase
activity, or through recruitment of members of the Janus
kinase (JAK) family to activated surface receptors. A direct
linkbetweenSTAT signalingand oncogenesiswasestablished
when it was shown that constitutive STAT activation by
oncogenic tyrosine kinases from Src or Abl families, directly
participates to cell transformation [93, 94]. Accordingly, a
large number of tumors, both in primary cells as well as
in tumor-derived cell lines, display constitutive activation of
STAT factors. In particular, STAT3 role in oncogenesis is well
documented in anaplastic large cell lymphoma where STAT3
activation was shown to provide growth advantage and
resistance to apoptosis of ALK+ tumor cells [81, 95, 96]. In
NKTCL, STAT3 was found constitutively activated, by phos-
phorylation on Y705, and localized in the nucleus in 90%
of the patients studied [24, 82]. Inhibition of endogenousJournal of Biomedicine and Biotechnology 5
Table 1: Recurrent genomic alterations in extranodal NKTCL from published data.
Chromosomal
location
Frequency (%)
Huang et al.
2010 [24]
Iqbal et al. 2009
[71]
Nakashim et al.
2005 [27]
Yoon and Ko
2003 [70]
Ko et al. 2001
[66]
Siu et al. 2000
[67]
Siu et al. 1999
[68]
Gains
1q21–q44 50 50 50 20
2q13-q14 26 24 29
2q31.1–q32.2 20 24 43
6p25–p11.1 40 25 40
7q11.2–q34 50 32 24 20
7q35-q36 60 40 40
17q21.1 20 50 29 40
20pter-qter 30 45 50
Losses
6 q 1 6 – q 2 5 4 05 03 88 0 4 92 5
11q23.1 30 13 29 31 20
11q24-q25 40 25 20
13q14.11 30 27 25 14 60
1 7 p 1 3 . 3 4 04 54 0 4 34 02 0
Table 2: Potential Therapeutic targets for extranodal NKTCL.
Pathways Genes Expression Chromosomallocation References
EBV LMP2-TR Up N.A. [32]
Survival/apoptosis
CCND3 Down 6p21.1 [69]
SERPINB9 Down 6p25 [19, 57]
FASL Up 1q23 [60, 78]
TNFAIP3 Down 6q23 [69, 79]
Cell signaling pathways
JAK-STAT STAT3 Up 17q21 [80, 81]
JAK2 Up 9p24 [69, 81]
IL10 Up 1q31-q32 [81, 82]
AKT AKT1/2/3 Up 14q32.3/19q13.1/1q44 [69, 70]
NOTCH NOTCH1 Up 9q34.3 [24, 83]
WNT β-CATENIN Up 3p22–p21.3 [24, 69]
PDGF PDGFRA Up 4q11–q13 [69]
PDGFA/B Up 7p22/22q12.3–q13.1 [69]
Angiogenesis
HGFR (MET) Up 7q31 [78]
VEGFR2 Up 4q12 [24, 69]
VEGFA Up 6q12 [24, 69]
HIF1α Up 14q21–q24 [24, 70, 84]
Tumor suppressor genes
del6q21 PRDM1 Down 6q21–q22.1 [70]
ATG5 Down 6q21 [70]
AIM1 Down 6q21 [70]
HACE1 Down 6q21 [69, 85]
Other pathways/genes
TP53 Down 17p13.1 [86, 87]
TP73 Down 1p36.3 [88]
AURKA Up 20q13 [24, 89]
N.A.: not applicable6 Journal of Biomedicine and Biotechnology
activated STAT3 in NKTCL-derived cell lines, using trans-
ducibledominant-negativeSTAT3,leadstogrowtharrestand
apoptosis inhibition [82]. These results are consistent with
the known targets of STAT3 transcriptional activities that
includesurvivin, cyclin D1, BCL-XL,c M Y C ,v a s c u l a rg r o w t h
factor (VEGF), IL-10, and IL-6 [97]. Importantly, STAT3
activation promotes the production of immunosuppressive
factors not only by the tumor cells but also by cells of
the microenvironment through mediators such as VEGF
or IL-10, activating STAT3 in these bystander cells that
in turn restrains antitumor immune response [84, 98].
Targeting STAT3 and/or JAK2 for cancer immunotherapy
may therefore be promising.
6.2.Angiogenesis Pathway. NKTCLischaracterized byangio-
centric growth and vascular damages with invasion of vessel
walls by lymphoma cells. In this context, a search for genes
associated with angiogenesisseems essential. The recent gene
expression proﬁling studies have recorded overexpression
of genes related to angiogenesis in NKTCL as compared
to other peripheral T cell lymphomas or normal NK cells
[24, 25]. Among those, one ﬁnds VEGFA an important
downstream product of STAT3, and its receptor VERGFR2
(KDR), both genes are upregulated, a ﬁnding conﬁrmed
by the immunohistochemical detection of VEGFα and
its receptor in tumor cells. As mentioned previously, the
production of VEGF by tumor cells not only may be used
for autocrine growth and survival but also to maintain
an immunosuppressive microenvironment by activating the
STAT3 pathway. Vascular destruction observed in nasal type
NKTCL results in hypoxia and the transcription activation
of HIFα (hypoxia-inducible factor 1), a transcriptional
activator that stimulates the expression of a number of
genes implicated in angiogenesis (including VEGFA and
VEGFR2)a n di no x y g e nh o m e o s t a s i s[ 78]. Also observed is
the upregulation of another important gene in angiogenesis,
the c-MET proto-oncogene that encodes the tyrosine kinase
cell surface receptor for the hepatocytegrowth factor (HGF).
HGF is a pleiotropic cytokine acting as an antiapoptotic,
a promigratory, and a proliferating factor for a number
of tissues. Interestingly, MET may be implicated in the
prevention of FAS-mediated apoptosis of the FAS-expressing
NKTCL tumors cells. This relies on the YLGA aminoacid
motif located near the N-terminal region of MET that
speciﬁcally binds to the extracellular portion of FAS and acts
as a FASLantagonist and inhibitor of FAS trimerization [99].
6.3. PDGFR Pathway. The platelet-derived growth factor
receptor- (PDGFR-) signaling pathway was also found
activated in NKTCL cells [24]. The overexpression of
PDGFRAmRNAin NKTCLcompared to normal NKcells in
microarray data is conﬁrmed by the expression of PDGFRα
and its phosphorylated form in primary tumors, shown
by immunohistochemistry. Neither genomic abnormalities
in the PDGFRA locus in 4q11–q13 nor mutations in the
coding sequence or anomalies in the promoter region
could be evidenced. The mechanism responsible for the
activation of the PDGFR remains therefore unclear, but
like in PTCL NOS (PTCL not otherwise speciﬁed) [83], an
autocrine feedback loop may explain the presence of the
phosphorylated PDGFRα observed in all the 13 NKTCL
cases examined. The potential of PDGF signaling pathway
in NKTCL cell proliferation is illustrated by the dramatic
dose-dependent inhibition of MEC04 cell growth observed
inculturesperformed thepresenceofimatinibmesylate [24].
6.4.Other Signaling Pathways. Pathwaysenrichedinthegene
signature of NKTCL include those of the NOTCH, WNT,
and NFκB signaling pathways [24, 25, 30]. However, and
particularly in this tumor where necrosis is associated with
strong inﬁltration of mesenchymal and lymphoid cells, it is
sometimes diﬃcult to attribute the diﬀerentially expressed
genestothetumorcellsratherthantothemicroenvironment
cells. In addition, diﬀerential expression needs conﬁrmation
in terms of biochemical activation. In particular, activation
of the WNT pathway, comprising genes involved during
the development and in oncogenesis, can be evidenced
by the nuclear translocation of β-catenin. However, no
nuclear expression of β-catenin could be observed in the
neoplastic cells in our study by Huang et al. [24], making the
targeting of WNT pathway of poor interest for therapeutic
purpose. On the other hand, activation of the NOTCH
pathway has been validated by Iqbal et al. [25]. NOTCH
signalsregulatedevelopmentanddiﬀerentiationofadultself-
renewing cells, including T cells. Gamma-secretase is a crit-
ical component of the NOTCH signal transduction pathway
[100]. Showing that inhibitors of γ-secretase can block the
proliferation and survival of NK cell lines in vitro, was used
for validation of NOTCH implication. Interestingly, PTEN
is a tumor suppressor gene encoding a lipid phosphatase
that antagonizes the activation of the PI3K/AKT pathway.
NOTCH1 controls a transcriptional network that leads to
activation of PI3K/AKT signaling and downmodulation of
PTENexpression.NOTCHsignalingandPI3K/AKTpathway
act synergistically to maintain oncogenic activity in T-cell
acute lymphoblastic leukemia [101]. PI3K/AKT was found
activated in microarray analysis of NKTCL, and nuclear
expression of phosphorylated-AKT was found in the nucleus
of most NKTCL samples. NFκBi sam a s t e rr e g u l a t o rt h a t
controls the expression of a number of genes. Because EBV
is known to activate NFκBt h r o u g hL M P - 1a n d / o rT R A F
signaling [79], upregulation of NFκBp a t h w a yi nN K T C L
versus normal NK cells is not unexpected. Signaling by
the transcription factor NFκB involves its release from its
inhibitor IκB, followed by its translocation into the nucleus.
Nuclear detection by immunohistochemistry of RelA, the
protein constituting the most abundant form of NFκB,
further supports the activation of this pathway in NKTCL.
Interestingly, the tumor necrosis factor-α-induced protein
gene,TNFAIP3, aninhibitorofNFκBactivity, wasalso found
downregulated in NKTCL. This gene is located in 6q23, the
region of recurrent loss discussed above, and loss of function
ofTNFAIP3havealsobeenreportedinHodgkin’slymphoma
and other B-cell lymphomas [86, 102]. Surprisingly, the
NFκB pathway genes were not enriched in the NKTCL gene
signature in the recent study of Iqbal et al. [25]. QuestionsJournal of Biomedicine and Biotechnology 7
remain, therefore, to clarify the value of this pathway to
identify therapeutic targets for NKTCL.
7.Other Pathwaysand CandidateTargetGenes
Many other genes are found diﬀerentially expressed or
targets for mutations or methylations in NKTCL when
compared to normal NK cells (see Table 2). The list includes
anumberofoncogenesortumorsuppressorgenesassociated
with many other tumors. TP53 is a well-known tumor
suppressor gene that causes cells with damaged DNA to
arrest at G1 phase of the cell cycle. TP53 is mutated
in many cancers, and the frequency of NKTCL-mutated
cases varies from 20 to 60%. TP53 mutated cases have
been associated with more advanced cases, suggesting that
TP53 mutation represents a secondary oncogenic event
rather than a triggering mechanism for the development of
NKTCL [87]. Nevertheless, TP53 is found underexpressed
in NKTCL transcriptomic analyses, and the observation
that EBNA1 promotes TP53 degradation [88]h a st ob e
considered to make TP53 pathway a possible target for
NKTCL therapy. TP73 belongs to the family of p53-related
proteins, which is involved in cell cycle arrest and apoptosis.
Methylation of TP73 has been reported in 94% of NKTCL
and has been proposed as a biomarker to detect NKTCL
involvement and metastasis [103]. MYC family genes encode
multifunctional nuclear phosphoproteins that function as
transcription factors to regulate expression of genes involved
in cell cycle progression such as CCNA2, CDKN1A,a n d
CDKN2B. Although frequent in hematopoietic and solid
tumors, mutations, ampliﬁcation, and translocation of this
oncogene have not been found in NKTCL. However, MYC
expression appears to be upregulated in the genesignature of
NKTCL.
Adhesion and cell-to-cell interaction molecules may
play an important role in tumor growth and homing in
view of the particular tropism of NKTCL for extranodal
sites. The molecular signatures reported for NKTCL in
comparison with normal NK cells include overexpression
of genes of the cadherin family (CDH1), of the integrin
f a m i l y( V C A M 1 ,I T G A 7 ,I T G A 9 ,a n dI T G B 4 ) ,a n do ft h e
sialoadhesin family (SIGLEC1, SIGLEC 9, SIGLEC11, and
SIGLECP3). Protocadherin 15 (PCDH15) was shown to be
expressed ectopically by NKTCL cells and NKTCL-derived
cell lines [104], and conﬁrmed in gene expression proﬁling
[24].PCDH15,normally absentin thehematopoietictissues,
may be used by NK tumor cells to escape immunosurveil-
lance, like CDH1 recognized by the KLRG1 inhibitory NK
receptor [105].
Recently, AURKA, the Aurora kinase A or ST6, was
reported as another potential target for NKTCL [25].
AURKAis a mitotic centrosomal protein kinase that controls
chromosome segregation during mitosis [89, 106]. AURKA
is activated by phosphorylation and could be detected in
all human NK cell lines tested, validating its transcriptomic
overexpression observed in NKTCL versus normal NK cells.
In many other cancers, AURKA upregulation results in a
phenotype characteristic of loss-of-function mutations of
TP53.Katayamaetal.showedthatTP53isphosphorylatedby
AURKA, inducing its ubiquitination by MDM2 and its pro-
teasomal degradation [107]. Thus, AURKAis a key regulator
ofTP53pathway,andtheAURKAinhibitorMK8751induced
cell cycle arrest and apoptosis in human cell lines, including
NKTCL-derived cell lines [25]. AURKA represent, therefore,
an interesting potential therapeutic target for NKTCL.
8.Conclusion
ANKLand NKTCLare EBV-associated malignancies of cyto-
toxic lymphocytes with poor prognosis and lack of eﬃcient
therapies. Their aggressive behavior and poor response to
chemotherapy make of paramount importance the search
for novel therapeutic targets in the treatment of these
lymphomas.NKTCLisararediseasealthoughmorefrequent
in Asia and South America, and the insuﬃcient supply of
tumor samples limits the developmentof an intense research
in that ﬁeld. In this context, malignant NK/T-cell lines
represent valuable tools to study these pathologies [108].
Genome-wide studies have generated new data improving
our understanding of the disease. Indeed, candidate tumor
suppressor genes, such as PRDMI, ATG5, AIM1,o rHACE1,
which can be inactivated by deletion and by methylation,
have been identiﬁed. The molecular signature of NKTCL
is distinct from that of other T-cell lymphoma subtypes.
Compared to normal NK cells, NKTCL is characterized by
activation of several pathways—PDGFRA, VEGFR, AKT,
JAK-STAT, and NOTCH—which might represent targets for
novel therapeutic options. Before settingup clinical trials,
extensive experimental validation of the potential target will
have to be undertaken using the available models. In this
respect, the study of tumor engrafting and development in
immunocompromised mice injected with NKTCL cell lines
or tumor fragments [82, 109] can be valuable models to test
new potential drugs and their in vivo activity. One can hope
that the eﬀorts of the researchers working to understand this
pathologywill soon lead toprogress in the treatment ofthese
lymphomas.
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